OncoMatch/Clinical Trials/NCT06381154
Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer
Is NCT06381154 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for locally advanced pancreatic adenocarcinoma.
Treatment: Fluorouracil · Irinotecan · Leucovorin · Oxaliplatin · Pembrolizumab · Photodynamic Therapy · Verteporfin — This phase II trial tests how well photoradiation with verteporfin and pembrolizumab plus standard of care chemotherapy works in treating patients with pancreatic cancer that cannot be removed by surgery (unresectable), that has spread to nearby tissue or lymph nodes (locally advanced) or to other places in the body (metastatic). Photoradiation uses light activated drugs, such as verteporfin, that become active when exposed to light. These activated drugs may kill tumor cells. Vertoporfin may also increase tumor response to immunotherapy. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as modified fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFIRINOX), work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Photoradiation with verteporfin and pembrolizumab plus standard of care chemotherapy may kill more tumor cells in patients with unresectable, locally advanced or metastatic pancreatic cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Disease stage
Required: Stage II, III, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: folfirinox
Lab requirements
Blood counts
Hemoglobin ≥ 9.0 g/dL; WBC ≥ 2500/mm^3; ANC ≥ 1500/mm^3; Platelet count ≥ 100,000/mm^3
Kidney function
Creatinine ≤ 1.5 x ULN OR calculated creatinine clearance ≥ 50 ml/min using the Cockcroft-Gault formula
Liver function
Total bilirubin ≤ 1.5 x ULN; ALT and AST ≤ 3 x ULN (≥ 5 x ULN for patients with liver involvement)
Hemoglobin ≥ 9.0 g/dL; WBC ≥ 2500/mm^3; ANC ≥ 1500/mm^3; Platelet count ≥ 100,000/mm^3; Total bilirubin ≤ 1.5 x ULN; ALT and AST ≤ 3 x ULN (≥ 5 x ULN for patients with liver involvement); Creatinine ≤ 1.5 x ULN OR calculated creatinine clearance ≥ 50 ml/min using the Cockcroft-Gault formula; Prothrombin time (PT) / INR / aPTT ≤ x ULN OR if patient is receiving anticoagulant therapy then INR or aPTT is within target range of therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic in Rochester · Rochester, Minnesota
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify